Cases & Deals

Vifor Pharma invests $50 million in Cara Therapeutics

Clients Vifor Pharma

Jones Day advised Vifor (International) Ltd., part of Vifor Pharma Group, a global pharmaceutical company, on its $50 million investment in Cara Therapeutics, Inc., a clinical stage biopharmaceutical company, as part of a licensing agreement for the commercialization of a drug used to treat chronic kidney disease-associated pruritus in the U.S. dialysis market.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.